Nucala is used to treat severe eosinophilic asthma, eosinophilic COPD, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (HES
In September 2019, the U.S. FDA approved Nucala for use in children as young as 6 years of age who have severe eosinophilic asthma. FDA approval is based on an open-label clinical trial (NCT02377427) which was conducted in 36 children aged 6 to 11 years who have severe asthma. Based ...